Print
Email
Print Edition StoriesThursday, June 18, 2009
Leerink Swann names Schimmer as biotech analyst
By MHT Staff
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Leerink Swann, a Boston-based boutique investment bank focused on the health care space, notes that Joshua Schimmer has joined the firm as managing director, biotechnology analyst, covering mid- and large-cap biotechnology companies.
Prior to joining Leerink Swann, Schimmer was a managing director for FTN Equity Capital Markets Corp., and prior to FTN he served as health care equities analyst for buy-side firm, Davidson Kempner Capital Management LLC. Previously Schimmer was a senior analyst in biotechnology for Cowen & Co., and began his career in biotechnology equity research at Deutsche Bank Securities.
Schimmer holds a doctor of medicine degree from the University of Toronto and an MBA from Harvard University. He completed his internal medicine residency at the University of Toronto, as well as a fellowship in rheumatology, where he was chief fellow.
Leerink Swann provides equity research, corporate finance, strategic advisory and asset management services for institutional, life sciences and high-net-worth clients. Among those clients are Waltham-based Inverness Medical Innovations Inc., Helicos BioSciences Corp. of Cambridge and Branford, Conn.-based Neurogen Corp.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
